Manufacturing Associate 3

Multispecifics are transforming the CDMO development architecture. August 28, 2026 | Manufacturers are being pushed beyond mAb-era platforms into a new design model built around molecular engineering, complex analytics and amplified upstream and downstream processing. The advent of multispecific antibody therapeutics has upended CDMO development architecture. To keep pace with their robust progress, manufacturers are adapting to a new design model built around molecular engineering, deep analytics and intensified upstream and downstream process configurations. Multispecifics are engineered biologics that can bind to more than one target at the same time. Bispecifics established the first generation of multitarget biologics. They have dominated trade news headlines as Chinese biotechs launched an unprecedented wave of bispecific programs between 2020 and 2025. During those years, CRDMOs and CDMOs such as WuXi Biologics, Lonza Biologics and Samsung Biologics announced technology platforms for developing bispecifics and multispecifics. The next wave of multispecifics include trispecifics, T-cell engagers with co-stimulation, NK engagers and dual agonists. Their development poses new challenges beyond bispecifics' inherent complexity - mispairing, instability and heterogeneity - and force CDMOs to revamp their development design and build. "The greatest impact with multispecific molecules is typically in cell line development (CLD), analytical characterization and downstream purification which will define a robust control strategy for manufacturing," said Laura Daley, senior director, Cell Biology & Product Development at Catalent. Molecular engineering changes. Multispecifics often struggle with chain mispairing and product heterogeneity. To address these concerns, engineering strategies such as knobs-into-holes are still frequently used as well as common light chains are often helpful, said Randal Bass, executive vice president, Process Design and Innovation at Just-Evotec Biologics. Knobs-into-holes is a bioengineering technique that modifies the shapes of two different protein halves so they fit together like matching puzzle pieces, ensuring they pair up correctly during manufacturing. While knobs-into-holes forces the two inner heavy chains to pair correctly, a common light chain uses the exact same piece for both outer light chains so they can never mispair. Multispecifics often require controlled expression of multiple chains at defined ratios, creating challenges that do not exist with traditional monoclonal antibodies, Daley said. Catalent has invested in its GPEx(R) Lightning platform to support complex biologics, including multispecifics, through precise control of gene integration, expression balancing and stable cell line generation. Of course, engineering the rest of the construct requires expertise, Bass said. "The domains you are trying to pull together, often Fab fragments, VHHs, a receptor or ligand fragment, also need to be stable," he said. Fab fragments and VHHs are small pieces of proteins derived from antibodies that bind to specific targets. "If you can get the fundamental pieces stable that makes putting them together easier," Bass said. Just-Evotec Biologics has a suite of in silico tools (Abacus) to help with these engineering tasks. The bioprocessing platforms themselves are becoming more amenable to multispecifics, Bass noted. CLD workflows employing high throughput transfections and automation makes screening multiple DNA vector chain ratios faster and easier. This assists in having the correctly assembled molecule. In terms of expression levels for trispecific formats compared to bispecifics or monoclonals, "few things are going to express as well as a fully human monoclonal antibody," Bass said. However, multispecifics are still going to express well in modern cell lines and vector systems. Additionally, with so much advancement with intensified bioreactor processes employing ATF or TFF perfusion, high volumetric productivity can be obtained. ATF and TFF are techniques used to retain living cells inside a bioreactor while continuously adding fresh nutrients and harvesting the liquid product (perfusion). Analytical capabilities crucial. New analytical methods have become essential for multispecific characterization. By far, mass spectrometry tools have become foundational, Bass said, adding that whole mass analysis and reduced whole mass analysis "can go a long way" to identify correctly paired molecules. Traditional size exclusion chromatography, coupled with nonreduced and reduced capillary electrophoresis, can mostly take care of quantifying impurities and the final assembled molecule, once it is characterized. Finally, the multiattribute method is indispensable as it detects bad modifications, as well as clipping sites that are more prevalent in complex molecules, Bass said. Multispecifics require significantly deeper analytical characterization than traditional monoclonal antibodies, Daley said. Key focus areas include chain pairing confirmation, structural characterization, variant identification, aggregate analysis and product heterogeneity assessment. Catalent has expanded integrated analytical development capabilities that support characterization and release testing throughout development and manufacturing, enabling rapid feedback loops between cell line development, process development and manufacturing. The rise of multispecifics has also changed CDMOs' quality control (QC) burdens, especially around binding and potency assays, Bass said. This is because some physical modifications to the multispecifics can affect binding to targets and subsequent potency. Thus, for every new target an assay can potentially be added. "Developers increasingly want faster decision-making, greater process understanding and reduced release timelines," Daley said. "While industry-wide adoption remains gradual, technologies such as process analytical technologies, automated data review, real-time process monitoring and AI-assisted analytics are becoming increasingly important." Upstream & downstream process development. Although intensified upstream technologies are gaining attention to increase productivity and shorten timelines, they are not always required to achieve commercial success, Daley said. Catalent's GPEx(R) Lightning technology routinely generates high-expressing cell lines across complex multispecific modalities in short timelines. It combines high-titer cell lines with an integrated development and manufacturing model. Many sponsors are requesting intensified upstream processes, such as perfusion and continuous feeding, Bass said. A challenge is that low titers, stability issues and proteolytic clipping can be common upstream issues with multispecifics, he said. By intensifying perfusion in the upstream process, low titers can be overcome. Additionally, a continuous capture step out of that reactor can mitigate proteolytic clipping and other stability concerns, like deleterious post-translation modification. Removing the molecule from the milieu of cell fragments, enzymes and metabolites in the bioreactor continuously is key, Bass said. For complex engineered multispecifics, they may contain molecular liabilities that could preclude them from being produced in a fed-batch process. Downstream is often the greater challenge than upstream, Daley noted. "Multispecifics frequently require molecule-specific purification strategies to address chain mispairing, aggregate control or product-related variants," she said. "Rather than redesigning facilities, successful CDMOs invest in flexible downstream infrastructure and high-throughput development capabilities that allow chromatography workflows to be rapidly optimized and scaled." Generally, the downstream process employs multiple chromatography steps (and even some depth filter removal of partial molecules) that can remove molecules that are not the final product, Bass said. While Just-Evotec Biologics has been able to use standard resins for this purification, it does employ scouting out more resins and more operating space to ensure complex multi-specifics can achieve an appropriate level of purity. "Fortunately, automation and plate-based or robo-column screening along with machine learned optimization analysis greatly aids finding the optimal resin and condition," Bass said.

Samanta Cimitan to become CCO of Lonza. Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President, and a member of the extended Executive Committee, effective January 1, 2027. Lonza has announced the appointment of Samanta Cimitan as Chief Commercial Officer (CCO), Senior Vice President, and member of the Extended Executive Committee. Cimitan will join the Swiss contract development and manufacturing organization (CDMO) no later than January 1, 2027. In this newly created role, she will oversee Strategic Enterprise Account Management, Global Marketing, and Commercial Excellence. She will also have direct commercial responsibility for Lonza's strategic customers and will work with the Commercial Excellence and Global Marketing teams to develop a unified market approach for the company. In line with the One Lonza strategy, the position is intended to help facilitate customer access to Lonza's global end-to-end offering across all three business platforms. Wolfgang Wienand, Chief Executive Officer of Lonza, stated: "The appointment of Samanta Cimitan as Chief Commercial Officer is another important step in building One Lonza and in harnessing the full power of the Lonza Engine for its partners in the pharmaceutical industry. Its goal is clear: Every customer should benefit from the unique breadth of its scientific, technological, and manufacturing expertise so that groundbreaking innovations can be translated into effective therapies for patients worldwide. Samanta Cimitan brings deep CDMO expertise, extensive experience in commercial leadership, and first-hand knowledge of Lonza. She knows how to build trusting partnerships, consistently deliver on commercial goals, and create value throughout the entire development and manufacturing chain. "I am very pleased to welcome Samanta back to Lonza as we continue to sharpen our commercial focus and pursue our goal of making the medicines of tomorrow a reality." Samanta Cimitan has many years of leadership experience in the CDMO industry and has built a successful career in sales strategy, customer partnerships, and operational execution. She is currently CEO of the Celonic Group, where she has driven the company's evolution into a focused biologics CDMO and strengthened its commercial, operational, regulatory, and innovation capabilities. Prior to joining Celonic, Cimitan worked at Lonza for nearly 13 years. There, she held various leadership positions in sales and strategy, including the role of Vice President of Group Operations Strategy. In this role, she developed and led transformation programs in sales, research & development, and manufacturing. Company. Muenchensteinerstrasse 38 4002 Basel Switzerland

Lonza launches rapid custom Media Prototyping Service to accelerate early bioprocess development. Monday, August 17, 2026 Lonza, the world's leading contract development and manufacturing organization (CDMO), today announced its Rapid Media Prototyping Service (RaMP), giving biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation and early development. With the possibility to send non-GMP powder batches from 1-10 kg and liquid batches from 1-100 L produced within 10 working days, the service helps scientists accelerate timelines, generate critical process data and prepare for GMP manufacturing. RaMP addresses common early development challenges, including long lead times for custom prototype media, limited small-batch manufacturing options and the need to align early formulation work with future manufacturing requirements. RaMP is part of Lonza's end-to-end custom media and buffer solutions offering, supporting customers from media development and screening through non-GMP prototyping and commercial GMP manufacturing. By linking early formulation work with long-term scalability, the service helps simplify development and support manufacturing readiness. Omar Wahab, Vice President, Head of Bioprocessing, Lonza, commented: "Development teams are under pressure to generate data quickly, make informed process decisions and keep programs moving toward the clinic. RaMP gives customers the possibility of rapid access to custom media in the quantities they need, when they need it. By connecting early screening and process confirmation with future GMP requirements, we help reduce scale-up risk, simplify technology transfer and support a more efficient path to commercialization." Delivered through Lonza's global media development and manufacturing network, RaMP combines rapid turnaround, flexible batch sizes and specialized expertise to help customers advance development with greater confidence while preparing for scale-up and GMP manufacturing. Further information about Lonza's custom media capabilities, including development, prototyping and manufacturing support, is available on the Lonza website: Custom media and buffer solutions | Lonza. Lonza Contact Details [email protected] About Lonza Lonza is the world's leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, Lonza's global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing. Its company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026. Find out more at www.lonza.com. Disclaimer Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this media advisory due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory. All trademarks belong to Lonza, and are registered in the USA, EU and/or CH, or used in common law, or belong to their respective third-party owners and are used for informational purposes only.